Machida T, Ikemoto I
Dept. of Urology, Jikei University School of Medicine.
Gan To Kagaku Ryoho. 1987 Oct;14(10):2845-52.
Endocrine therapy for urological tumor includes estrogen therapy for prostatic carcinoma. This endocrine therapy is one of the most firmly established therapeutic methods in the field of clinical oncology. However, confusion exists about how long this treatment remains effective and whether it prolongs survival, since estrogen can create cardiovascular complications in patients with prostatic carcinoma. Recently, new endocrine agents have been developed to compensate for the problems of estrogen therapy and to make treatment more effective. Estramustine sodium phosphate is medicine for internal use prepared by combining estradiol with nitrogen mustard. This hormonal chemotherapeutic agent has proved effective in 98% of treated patients. Most of the side effects of this agent have been observed in the digestive organs. Chlormadinone acetate, a progestational agent, has proved more effective against early prostatic carcinoma than against late-stage disease. LHRH analogue, which is now drawing much attention as a "chemical castration" agent for prostatic cancer patients, exerts an effectiveness equal to medium-dose estrogen treatment. The above three agents for the treatment of prostatic carcinoma should become increasingly popular in the future.
泌尿外科肿瘤的内分泌治疗包括前列腺癌的雌激素治疗。这种内分泌治疗是临床肿瘤学领域中最成熟的治疗方法之一。然而，对于这种治疗的有效时长以及它是否能延长生存期仍存在困惑，因为雌激素会给前列腺癌患者带来心血管并发症。最近，新型内分泌药物已被研发出来，以弥补雌激素治疗的问题并提高治疗效果。磷酸雌莫司汀是通过将雌二醇与氮芥结合而制成的内服药物。这种激素化疗药物已被证明对98%的接受治疗的患者有效。该药物的大多数副作用出现在消化器官。醋酸氯地孕酮，一种孕激素，已被证明对早期前列腺癌比对晚期疾病更有效。促性腺激素释放激素类似物，作为一种用于前列腺癌患者的“化学去势”药物目前备受关注，其疗效等同于中等剂量的雌激素治疗。上述三种治疗前列腺癌的药物在未来应该会越来越受欢迎。
